Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
NCT02950922Phase 2Completed
- Sponsor
- Dermavant Sciences
- Start
- Nov 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of tapinarof in atopic dermatitis (AD) (3 arms), sponsored by Dermavant Sciences. Primary endpoints: Frequency and severity of adverse events (local and systemic) at 28 days, Laboratory values at 28 days and 4 more. Started Nov 2016; status: completed.
02
Drugs
tapinarof
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02950922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02950922.